Key facts
- Owkin’s last known valuation is $1.6B (Jun 2022).
- It has raised $334.1M; the latest was Later Stage VC in Dec 2024.
- Notable investors include Plug and Play Tech Center, Bpifrance, GV, F-Prime Capital, Eight Roads — 22 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 22 names
- ·Watchlist + deal alerts for Owkin
- ·The full record, as it builds
Funding rounds
No funding rounds for Owkin are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Owkin
Developer of an artificial intelligence agent system intended to analyze biological patient data and to support drug discovery and clinical research. The company offers artificial intelligence research agents, biological data analysis tools, digital pathology diagnostics, drug discovery software, clinical research analytics, and biomedical knowledge agents, enabling pharmaceutical companies and researchers to analyze patient data, identify drug candidates, and support clinical trial development.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2016
- Employees
- 325
- Website
- owkin.com/
- Ownership
- Privately Held (backing)
Owkin doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Owkin shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Owkin in its N-PORT filings yet. We sweep new filings monthly.